1.	Phase II/III Randomized Study of CC-5013 in Patients With Progressive or Relapsed Metastatic Malignant Melanoma Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0210051, CELGENE-CDC-501-MEL-001, MSKCC-03026, NCT00060281
2.	S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000306449, U10CA032102, S0232, SWOG-S0232, NCT00064038
3.	Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma. Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MEL-002, NCT00057616
4.	Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2003-35, NCT00093028
5.	Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: CDR0000434845, U10CA031946, CALGB-100104, ECOG-CALGB-100104, NCT00114101
6.	Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MDS-004, 2005-000454-73, NCT00179621
7.	A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older Phase: Phase III Type: Treatment Status: Closed Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-015, 2006-001865-41, NCT00405756
8.	Maintenance Therapy Using Lenalidomide in Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: 0400401, French PHRC, NCT00430365
9.	A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-018, 2006-002517-12, NCT00420849
10.	QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2007-000649-36, QUIREDEX, NCT00480363
11.	Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00521, U10CA021115, CDR0000561758, E1A05, ECOG-E1A05, NCT00522392
12.	Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: RV-MM-PI-209, NCT00551928
13.	Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Phase: Phase III Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00522, U10CA021115, CDR0000583984, E1A06, ECOG-E1A06, NCT00602641
14.	Phase III Randomized Study of Lenalidomide and Low-Dose Dexamethasone With Versus Without Bortezomib in Patients With Previously Untreated Multiple Myeloma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0777, S0777, NCT00644228
15.	Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-020, NCT00689936
16.	CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-009, NCT00056160
17.	A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-010, NCT00424047
18.	A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Subjects With Previously Treated Multiple Myeloma Phase: Phase III Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-022, NCT00928486
19.	Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000404161, ECOG-E4A03, E4A03, NCT00098475
20.	Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-PC-002, EudraCT Number 2008-007969-23, NCT00988208
21.	Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-009, NCT01080391
22.	Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-OVRY-002, NCT00179712
23.	Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CASE17Z05, P30CA016042, UCLA-0511032-01, UCLA-RDN-5405, UCLA-05011032-01, NCT00352001
24.	Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: J0798, RV-PCA-PI-069, NCT00348595
25.	Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 06-150, NCT00378105